Your browser doesn't support javascript.
loading
Factors associated with skin cancer in lung transplant recipients: A single-center experience.
Elnahas, Shaimaa; Olson, Michael T; Kang, Paul; Panchanathan, Roshan; Masuda, Takahiro; Walia, Rajat; Zeitouni, Nathalie C; Smith, Michael A; Bremner, Ross M.
Afiliação
  • Elnahas S; Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
  • Olson MT; Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
  • Kang P; University of Arizona College of Medicine, Phoenix, Arizona.
  • Panchanathan R; University of Arizona College of Public Health, Phoenix, Arizona.
  • Masuda T; University of Arizona College of Medicine, Phoenix, Arizona.
  • Walia R; Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
  • Zeitouni NC; Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
  • Smith MA; Department of Dermatology, University of Arizona College of Medicine, Phoenix, Arizona.
  • Bremner RM; Norton Thoracic Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Clin Transplant ; 33(12): e13718, 2019 12.
Article em En | MEDLINE | ID: mdl-31545540
ABSTRACT

BACKGROUND:

Skin cancer is common after solid organ transplantation, but few have investigated it after lung transplant (LTx).

OBJECTIVE:

We assessed incidence and predictors of non-melanoma skin cancer (NMSC) post-LTx.

METHODS:

We studied patients who underwent LTx at our center from 2012 to 2015.

RESULTS:

Of 287 patients, mean age was 59.6 ± 11 years, 170 (59.2%) were men, and 231 (80.5%) were white. Seventy-six (26.5%) developed NMSC over a median follow-up of 32 months (IQR, 23-45). Of those with NMSC, 37% developed subsequent skin cancer of the same type. Independent predictors of decreased odds of NMSC and squamous cell carcinoma (SCC) were non-white race (P = .002; P = .003) and body mass index >30 kg/m2 compared with underweight patients (P = .001, P = .009). Patients with skin cancer pre-LTx had higher risk of post-LTx skin cancer (P = .02). Voriconazole use ≥100 days was associated with increased risk of SCC (P = .03), but not increased risk of basal cell carcinoma. Out of 76, 4 (5.3%) died from skin cancer.

LIMITATIONS:

Retrospective, single-center study.

CONCLUSION:

Squamous cell carcinoma risk post-LTx may increase with prolonged voriconazole use in white patients with pre-LTx history of skin cancer, whereas excess body weight may be protective from NMSC. Regular pre- and post-LTx skin cancer screenings and guidelines are warranted.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Ano de publicação: 2019 Tipo de documento: Article